Healthcare provider profile · identity verified

Aleida M Rivera, MD

Family Practice · OXFORD, MI · NPI 1528022175

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	352	115
Levothyroxine Sodium	Levothyroxine Sodium	306	85
Losartan Potassium	Losartan Potassium	220	70
Omeprazole	Omeprazole	218	62
Amlodipine Besylate	Amlodipine Besylate	199	60
Rosuvastatin Calcium	Rosuvastatin Calcium	192	70
Metformin Hcl	Metformin Hcl	153	46
Lisinopril	Lisinopril	148	48
Metoprolol Succinate	Metoprolol Succinate	126	30
Alendronate Sodium	Alendronate Sodium	115	32
Gabapentin	Gabapentin	102	31
Hydrochlorothiazide	Hydrochlorothiazide	94	30
Fluticasone Propionate	Fluticasone Propionate	91	38
Simvastatin	Simvastatin	91	25
Escitalopram Oxalate	Escitalopram Oxalate	86	22
Alprazolam	Alprazolam	81	30
Albuterol Sulfate Hfa	Albuterol Sulfate	80	34
Meloxicam	Meloxicam	75	23
Famotidine	Famotidine	74	30
Metoprolol Tartrate	Metoprolol Tartrate	68	20
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	63	12
Buspirone Hcl	Buspirone Hcl	61	14
Ropinirole Hcl	Ropinirole Hcl	59	11
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	58	18
Sertraline Hcl	Sertraline Hcl	57	16
Ezetimibe	Ezetimibe	55	22
Bupropion Hcl Sr	Bupropion Hcl	50	13
Allopurinol	Allopurinol	48	16
Eliquis	Apixaban	48	13
Prednisone	Prednisone	48	40
Duloxetine Hcl	Duloxetine Hcl	46	14
Ibuprofen	Ibuprofen	46	14
Methocarbamol	Methocarbamol	45	23
Potassium Chloride	Potassium Chloride	42	15
Irbesartan	Irbesartan	39	11
Metformin Hcl Er	Metformin Hcl	39	12
Chlorthalidone	Chlorthalidone	38	11
Mirtazapine	Mirtazapine	38	12
Pantoprazole Sodium	Pantoprazole Sodium	38	11
Citalopram Hbr	Citalopram Hydrobromide	35	suppressed
Furosemide	Furosemide	35	suppressed
Tramadol Hcl	Tramadol Hcl	34	suppressed
Trelegy Ellipta	Fluticasone/Umeclidin/Vilanter	34	suppressed
Jardiance	Empagliflozin	33	12
Pravastatin Sodium	Pravastatin Sodium	32	13
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	31	suppressed
Montelukast Sodium	Montelukast Sodium	31	suppressed
Clopidogrel	Clopidogrel Bisulfate	29	suppressed
Cyclobenzaprine Hcl	Cyclobenzaprine Hcl	29	suppressed
Ozempic	Semaglutide	29	11
Bupropion Xl	Bupropion Hcl	28	suppressed
Fluoxetine Hcl	Fluoxetine Hcl	28	suppressed
Amlodipine Besylate-Benazepril	Amlodipine Besylate/Benazepril	27	suppressed
Tamsulosin Hcl	Tamsulosin Hcl	27	suppressed
Raloxifene Hcl	Raloxifene Hcl	26	suppressed
Trazodone Hcl	Trazodone Hcl	26	14
Mupirocin	Mupirocin	25	20
Carvedilol	Carvedilol	24	suppressed
Lidocaine	Lidocaine	24	suppressed
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	23	suppressed
Zolpidem Tartrate	Zolpidem Tartrate	23	suppressed
Azithromycin	Azithromycin	22	22
Sulfamethoxazole-Trimethoprim	Sulfamethoxazole/Trimethoprim	22	19
Xarelto	Rivaroxaban	22	suppressed
Benazepril Hcl	Benazepril Hcl	21	suppressed
Nystatin	Nystatin	21	suppressed
Synthroid	Levothyroxine Sodium	21	suppressed
Ventolin Hfa	Albuterol Sulfate	21	suppressed
Dicyclomine Hcl	Dicyclomine Hcl	20	suppressed
Lansoprazole	Lansoprazole	20	suppressed
Amoxicillin-Clavulanate Potass	Amoxicillin/Potassium Clav	19	16
Celecoxib	Celecoxib	19	suppressed
Clonazepam	Clonazepam	19	suppressed
Fentanyl	Fentanyl	19	suppressed
Glipizide	Glipizide	19	suppressed
Levetiracetam	Levetiracetam	19	suppressed
Pioglitazone Hcl	Pioglitazone Hcl	19	suppressed
Spironolactone	Spironolactone	19	suppressed
Triamcinolone Acetonide	Triamcinolone Acetonide	19	16
Acetaminophen-Codeine	Acetaminophen With Codeine	18	suppressed
Amoxicillin	Amoxicillin	18	17
Dextroamphetamine-Amphetamine	Dextroamphetamine/Amphetamine	18	suppressed
Ondansetron Hcl	Ondansetron Hcl	18	suppressed
Oxybutynin Chloride Er	Oxybutynin Chloride	18	suppressed
Atenolol	Atenolol	17	suppressed
Lorazepam	Lorazepam	17	suppressed
Doxazosin Mesylate	Doxazosin Mesylate	16	suppressed
Ketoconazole	Ketoconazole	16	suppressed
Nifedipine Er	Nifedipine	16	suppressed
Diltiazem 24hr Er (Cd)	Diltiazem Hcl	15	suppressed
Lovastatin	Lovastatin	15	suppressed
Nitrofurantoin Mono-Macro	Nitrofurantoin Monohyd/M-Cryst	15	13
Tiotropium Bromide	Tiotropium Bromide	15	suppressed
Amitriptyline Hcl	Amitriptyline Hcl	14	suppressed
Glimepiride	Glimepiride	14	suppressed
Hydralazine Hcl	Hydralazine Hcl	14	suppressed
Hydroxyzine Hcl	Hydroxyzine Hcl	14	suppressed
Quetiapine Fumarate	Quetiapine Fumarate	14	suppressed
Atenolol-Chlorthalidone	Atenolol/Chlorthalidone	13	suppressed
Januvia	Sitagliptin Phosphate	13	suppressed
Paxlovid	Nirmatrelvir/Ritonavir	13	13
Chlorhexidine Gluconate	Chlorhexidine Gluconate	12	suppressed
Liothyronine Sodium	Liothyronine Sodium	12	suppressed
Ramipril	Ramipril	12	suppressed
Bumetanide	Bumetanide	11	suppressed
Enalapril Maleate	Enalapril Maleate	11	suppressed
Fluconazole	Fluconazole	11	suppressed
Mounjaro	Tirzepatide	11	suppressed
Trulicity	Dulaglutide	11	suppressed
Valacyclovir	Valacyclovir Hcl	11	suppressed
Venlafaxine Hcl Er	Venlafaxine Hcl	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error